Status:
UNKNOWN
Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer
Lead Sponsor:
Peking University First Hospital
Conditions:
Obstructive Sleep Apnea
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This prospective, observational cohort study aims to explore the influence of obstructive sleep apnea(OSA) on the efficacy of PD-1-based immunotherapy in patients with non-small cell lung cancer(NSCLC...
Detailed Description
This is a single-center, prospective, observational cohort study. Patients who had no prior treatment for advanced NSCLC and are intended to receive PD-1/PD-L1 antibody will be recruited and followed ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed, advanced NSCLC
- Participants with no prior treatment for advanced NSCLC
- Measurable disease as defined by RECIST v1.1
- Eligible to receive first-line treatment including PD-1 antibody
- Adequate hematologic and end organ function
Exclusion
- Severe infection within 4 weeks prior to recruitment.
- Significant organ dysfunction or other serious diseases.
- Previous or current OSA related treatment, including oral appliance, surgery, mechanical ventilation therapy.
- Illness or condition that interferes with the participant's capacity to understand, follow and/or comply with study procedures.
Key Trial Info
Start Date :
February 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04743752
Start Date
February 23 2021
End Date
December 31 2025
Last Update
April 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034